Consensus of experts from the Spanish Pharmacogenetics and Pharmacogenomics Society and the Spanish Society of Medical Oncology for the genotyping of DPYD in cancer patients who are candidates for treatment with fluoropyrimidines
García-Alfonso, Pilar (Hospital General Universitario Gregorio Marañón)
Saiz-Rodríguez, M. (Hospital Universitario de Burgos)
Mondéjar, R. (Hospital Universitario de la Princesa (Madrid))
Salazar, Juliana (Institut d'Investigació Biomèdica Sant Pau)
Páez, David (Institut d'Investigació Biomèdica Sant Pau)
Borobia, Alberto M (Hospital Universitario La Paz (Madrid))
Safont, M. J. (Universitat de València)
García-García, Irene (Hospital 12 de Octubre (Madrid))
Colomer, Ramon (Hospital Universitario de la Princesa (Madrid))
García-González, Xandra (Hospital General Universitario Gregorio Marañón)
Herrero Cervera, María José (Universitat de València)
López-Fernández, L. A. (Hospital General Universitario Gregorio Marañón)
Abad-Santos, Francisco (Hospital Universitario de la Princesa (Madrid))
Universitat Autònoma de Barcelona

Date:	2021
Abstract:	5-Fluorouracil (5-FU) and oral fluoropyrimidines, such as capecitabine, are widely used in the treatment of cancer, especially gastrointestinal tumors and breast cancer, but their administration can produce serious and even lethal toxicity. This toxicity is often related to the partial or complete deficiency of the dihydropyrimidine dehydrogenase (DPD) enzyme, which causes a reduction in clearance and a longer half-life of 5-FU. It is advisable to determine if a DPD deficiency exists before administering these drugs by genotyping DPYD gene polymorphisms. The objective of this consensus of experts, in which representatives from the Spanish Pharmacogenetics and Pharmacogenomics Society and the Spanish Society of Medical Oncology participated, is to establish clear recommendations for the implementation of genotype and/or phenotype testing for DPD deficiency in patients who are candidates to receive fluoropyrimidines. The genotyping of DPYD previous to treatment classifies individuals as normal, intermediate, or poor metabolizers. Normal metabolizers do not require changes in the initial dose, intermediate metabolizers should start treatment with fluoropyrimidines at doses reduced to 50%, and poor metabolizers are contraindicated for fluoropyrimidines.
Rights:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Language:	Anglès
Document:	Article ; recerca ; Versió publicada
Subject:	5-fluorouracil ; Capecitabine ; Dihydropyrimidine dehydrogenase ; Genotypes ; Pharmacogenetics ; Toxicity
Published in:	Clinical & translational oncology, Vol. 24 (november 2021) , p. 483-494, ISSN 1699-3055

DOI: 10.1007/s12094-021-02708-4
PMID: 34773566

12 p, 926.4 KB

The record appears in these collections:
Research literature > UAB research groups literature > Research Centres and Groups (research output) > Health sciences and biosciences > Institut de Recerca Sant Pau
Articles > Research articles
Articles > Published articles